542 results on '"Howlett, Jonathan G"'
Search Results
2. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
3. Integration of longitudinal and circumferential strain predicts volumetric change across the cardiac cycle and differentiates patients along the heart failure continuum
4. Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients
5. The Need for Fiber Addition in Symptomatic Heart Failure (FEAST-HF): A Randomized Controlled Pilot Trial
6. Right Ventricular Systolic Pressure Trajectory as a Predictor of Hospitalization and Mortality in Patients With Chronic Heart Failure
7. Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes
8. Abstract 14430: The Corcare Heart Function Optimization Protocol: A Structured Quality Improvement Intervention to Improve Goal Directed Targets for Patients With Reduced Ejection Fraction
9. Clinical Phenotypes of Heart Failure across the spectrum of Ejection Fraction: A Cluster Analysis
10. Machine Learning For Risk Prediction After Heart Failure Emergency Department Visit or Hospital Admission Using Administrative Health Data.
11. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
12. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
13. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
14. Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.
15. Computerized Electronic Order Set: Use and Outcomes for Heart Failure Following Hospitalization
16. Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
17. The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey
18. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children
19. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis
20. Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis
21. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
22. Factors Influencing Clinical Initiation of Tafamidis Therapy for Transthyretin Amyloidosis Cardiomyopathy: A Canadian Referral Center Experience
23. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial
24. Outcomes in patients undergoing cardiac retransplantation: A propensity matched cohort analysis of the UNOS Registry
25. Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis
26. Un(b)locking therapeutic options: potential for calcium channel blockers in heart failure with non‐reduced left ventricular ejection fraction
27. Feasibility of Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial
28. Prognostic Value of Right Ventricular Strain Using Speckle-Tracking Echocardiography in Pulmonary Hypertension: A Systematic Review and Meta-analysis
29. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
30. Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial
31. What Difference Does a Day Make?
32. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
33. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
34. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
35. Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population
36. Predicting Heart Failure With Reduced or Preserved Ejection Fraction From Health Records
37. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)
38. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
39. The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice
40. NOVEL HFREF ALGORITHM DEMONSTRATES A SAFE AND EFFECTIVE STRATEGY FOR RAPID GDMT TITRATION
41. Is it time to relitigate SGLT2 Inhibitor dose for heart failure?
42. Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure
43. Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms
44. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis
45. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
46. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications
47. Hematopoietic Cell Transplantation for Systemic Sclerosis—A Review
48. The International Endomyocardial Biopsy Position Paper: A Basis for Integration Into Modern Clinical Practice
49. Amyloidosis Tissue Confirmation for Tafamidis Eligibility Using Transverse Carpal Ligament and Tenosynovium Biopsy
50. Can Machines Find the Sweet Spot in End-Stage Heart Failure?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.